Moderna Q3 2026 Results: Net Income $162 Million on Revenue of $1.31 Billion
- US stocks
- Earnings
- Health Care

For the third quarter of 2026, Moderna (Nasdaq: MRNA) reported GAAP revenue of $1.31 billion and GAAP net income of $162.0 million, it said on 6 Nov 2026. Diluted EPS was $0.38 on a GAAP basis, against a loss of $0.51 per share a year earlier.
Key highlights
- Revenue (GAAP): $1.31 billion, up 29.2% YoY
- Net income (GAAP): $162.0 million, against -$200.0 million a year earlier
- Diluted EPS (GAAP): $0.38, against -$0.51 a year earlier
- Operating income (GAAP): $130.0 million, against -$260.0 million a year earlier
- Cash, cash equivalents and investments: $8.0 billion at 30 Sep 2026
Summary
| Particulars | Q3 2026 | Q3 2025 | YoY | Q2 2026 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,313.0 | 1,016.0 | +29.2% | 145.0 | +805.5% |
| 130.0 | -260.0 | n/a | -815.0 | n/a | |
| Operating margin | 9.90% | -25.59% | +35.49 pp | -562.07% | +571.97 pp |
| 162.0 | -200.0 | n/a | -782.0 | n/a | |
| Net income margin | 12.34% | -19.69% | +32.03 pp | -539.31% | +551.65 pp |
| Diluted EPS ($) | 0.38 | -0.51 | n/a | -1.97 | n/a |
Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.
The table sets the third quarter of 2026 against the same quarter of 2025. Revenue rose 29.2%, from $1,016.0 million to $1,313.0 million. GAAP operating margin was 9.90%, against -25.59% a year earlier, a gain of 35.49 percentage points.
GAAP net income margin was 12.34%, against -19.69% a year earlier, a change of 32.03 percentage points.
Revenue rose on international COVID vaccine sales
The company said revenue rose 29% to $1.3 billion, mainly on higher international COVID vaccine sales, which it tied to deliveries under long-term government partnerships. Revenue was $780 million in the U.S. and $533 million in international markets.
Net product sales were $1.27 billion and other revenue was $40.0 million. In September, Moderna also agreed a five-year deal with a local Mexican manufacturer to supply COVID-19 vaccines.
Research and development spending fell 27%
Research and development expenses were $583 million, down 27% from a year earlier. The company said this mainly came from lower clinical development costs after certain late-stage infectious disease studies were completed and wound down, along with cost efficiencies across the organization.
Cost of sales was $318 million, up 54%, including $65 million of third-party royalties. The company attributed the rise mainly to higher product sales volume and other manufacturing-related costs. Selling, general and administrative expenses were $282 million, up 5%.
Revenue outlook raised and year-end cash guidance increased
Moderna raised its 2026 revenue growth forecast to a range of 15% to 25%, from up to 10% previously. It also expects roughly half of 2026 revenue to be US-based and half international.
Year-end 2026 cash and investments are now forecast at $8.1 billion to $8.3 billion, up from $4.7 billion to $5.2 billion. It said the increase came from improved operational execution and proceeds from its convertible notes financing, and that the outlook excludes further drawdowns from about $0.9 billion remaining under its credit facility.
Cash, cash equivalents and investments were $8.0 billion at 30 Sep 2026, against $6.9 billion at 30 Jun 2026. The company said the rise mainly came from $2.6 billion in net proceeds from convertible notes and related capped call transactions, partly offset by a $950 million litigation settlement payment and cash used in operations.
Inference
Diluted weighted average shares were 430 million in the quarter, against 390 million a year earlier, and the release gives no dividend or share buyback for the period.
The release gives no adjusted EPS and no quarter-end share count. The next dated step it gives is the Analyst Day on 12 Nov 2026.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

